Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216145 | 0.92 | MAOB (0.43) | MAOBL3MBTL1GAAHTTSMN1; SMN2 | |
| SCHEMBL4220858 | 0.92 | MAOB (0.42) | MAOBMAOAL3MBTL1GAAHTT | |
| SCHEMBL4218108 | 0.90 | HTT (0.44) | MAOBMAOAL3MBTL1GAAHTT | |
| SCHEMBL4218634 | 0.87 | MAOB (0.40) | MAOBMAOAL3MBTL1 | |
| SCHEMBL5044605 | 0.85 | THRB (0.43) | MAOBL3MBTL1GAAHTTSMN1; SMN2 | |
| SCHEMBL4044613 | 0.84 | PARP1 (0.34) | PARP1PARP3ATM | |
| SCHEMBL4044618 | 0.84 | PARP1 (0.34) | PARP1PARP3ATM | |
| SCHEMBL14011438 | 0.83 | PARP1 (0.36) | PARP1PARP3 | |
| SCHEMBL4220932 | 0.83 | HTT (0.46) | MAOBL3MBTL1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4221109 | 0.81 | ALDH1A1 (0.41) | MAOBMAOAL3MBTL1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | MAOB 962/4885MAOA 751/4885L3MBTL1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.